Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 236 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Anticoagulation Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation

NCT02047565
View directory record Official record
Conditions
Bleeding
Interventions
60mg edoxaban, 180mg edoxaban, 50 IU/kg Beriplex P/N, 25 IU/kg Beriplex P/N, 10 IU/kg Beriplex P/N
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional

A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome

NCT00932100
View directory record Official record
Conditions
Acute Coronary Syndrome (ACS)
Interventions
REG1, Heparin
Drug
Lead sponsor
Regado Biosciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
26
States / cities
Huntsville, Alabama • Sacramento, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2012 · Synced Oct 23, 2026, 8:22 AM EDT
Recruiting No phase listed Observational

Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization

NCT03407469
View directory record Official record
Conditions
Cancer-related Venous Thromboembolism
Interventions
Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 23, 2026, 8:22 AM EDT
Recruiting Not applicable Interventional

Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Thrombosis and Its TrEatment With Anticoagulation

NCT02318342
View directory record Official record
Conditions
Prosthetic Valve Thrombosis
Interventions
Warfarin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 23, 2026, 8:22 AM EDT
Completed No phase listed Observational Results available

Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy?

NCT02900170
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Not listed
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
60 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 23, 2026, 8:22 AM EDT
Enrolling by invitation Not applicable Interventional

Storytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation

NCT05997914
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Adherence, Medication, Anticoagulants and Bleeding Disorders, Stroke, Bleeding, Narration
Interventions
Storytelling Intervention
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Jacksonville, Florida • Worcester, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 1 Interventional

Treatment for Blood Clots in the Veins of the Legs

NCT00001713
View directory record Official record
Conditions
Embolism, Thrombophlebitis
Interventions
Recombinant Tissue Plasminogen Activator, Heparin, Warfarin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 4 Interventional Results available

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma

NCT02958969
View directory record Official record
Conditions
Venous Thromboembolism, Multiple Myeloma
Interventions
Apixaban
Drug
Lead sponsor
Gregory Piazza
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Not applicable Interventional

Anticoagulation, Vitamins, and Endothelial Function

NCT00018460
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Vitamin B
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin

NCT00927862
View directory record Official record
Conditions
Thromboembolism
Interventions
IWPC adapted genotype-guided dosing algorithm for warfarin, Modified IWPC genetic-guided warfarin dosing algorithm, Standard of care treatment
Genetic · Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Not applicable Interventional

Using Artificial Intelligence to Measure and Optimize Adherence in Patients on Anticoagulation Therapy.

NCT02599259
View directory record Official record
Conditions
Stroke
Interventions
Monitored (M+)
Device
Lead sponsor
AiCure
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

NCT01561937
View directory record Official record
Conditions
Haemostasis, Healthy
Interventions
warfarin, eptacog alfa (activated), placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 23, 2026, 8:22 AM EDT
Completed No phase listed Observational

Eliminate Thromboembolism: Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients

NCT02461602
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Pasadena, California • Coral Springs, Florida • Port Charlotte, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Not applicable Interventional Results available

Improving Anticoagulation Control in VISN 1

NCT01653405
View directory record Official record
Conditions
Anticoagulants, Atrial Fibrillation, Venous Thromboembolism
Interventions
Multifaceted behavioral intervention
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
1,260,576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 1 Interventional

Safety and Dosing Evaluation of REG1 Anticoagulation System

NCT00113997
View directory record Official record
Conditions
Healthy
Interventions
REG1
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improved Time in Therapeutic Range With Patient Self-Testing of Their INR Compared to Usual Care

NCT00703963
View directory record Official record
Conditions
Management of Anticoagulation
Interventions
INRatio monitor by Hemosense, Usual Care
Device · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Oct 23, 2026, 8:22 AM EDT
Recruiting No phase listed Observational

Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)

NCT06844227
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
Not listed
Lead sponsor
McMaster University
Other
Eligibility
18 Years to 100 Years
Enrollment
1,780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Evanston, Illinois • Detroit, Michigan • Great Neck, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 23, 2026, 8:22 AM EDT
Completed No phase listed Observational

ImplemeNtation oF demOnstration pRoject for Health systeMs: Atrial Fibrillation (INFORM-AF) Part 1

NCT02569528
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 2 Interventional

Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI

NCT00715455
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
REG1, Unfractionated Heparin
Drug
Lead sponsor
Regado Biosciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Indianapolis, Indiana • Detroit, Michigan • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 23, 2026, 8:22 AM EDT
Completed No phase listed Observational

Understanding and Improving Anticoagulation Dosing for Patients With Atrial Fibrillation

NCT03719144
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 23, 2026, 8:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study

NCT01747746
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Thrombo-embolism, Bleeding
Interventions
Rivaroxaban, Warfarin and Enoxaparin
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Oct 23, 2026, 8:22 AM EDT
Completed No phase listed Observational

Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation

NCT04351438
View directory record Official record
Conditions
Therapeutic Plasma Exchange, Anticoagulant Therapy
Interventions
Active Comparator: centrifuge TPE with citrate, Active Comparator: Filter TPE with heparin, Active comparator: Filter TPE with citrate
Device · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
0 Years to 24 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 23, 2026, 8:22 AM EDT
Completed No phase listed Observational

Global Anticoagulant Registry in the Field

NCT01090362
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Thrombosis Research Institute
Other
Eligibility
18 Years and older
Enrollment
57,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 23, 2026, 8:22 AM EDT
Recruiting Not applicable Interventional

The PERSEVERE Study

NCT06588634
View directory record Official record
Conditions
Pulmonary Embolism, Pulmonary Thromboembolism
Interventions
FlowTriever System, Standard of Care
Device · Procedure
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
16
States / cities
New Haven, Connecticut • Orlando, Florida • Sarasota, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 8:22 AM EDT